Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Nurses May Be Key to Long-Term Clinical Trial Success

Lara C. Pullen, PhD  |  July 6, 2015

NursePatient_Slider2_JacobWackerhausen_iStockphotoPhysicians often have trouble motivating patients to continue participating in long-term, follow-up studies. Unfortunately, this results in reduced insight into evolving outcomes of interventions, late side effects and rare events. Iris M. Markusse, MD, a rheumatologist at the Leiden University Medical Center in The Netherlands, and colleagues questioned patients to determine what factors were associated with long-term participation in a clinical trial. Their results were published in the June 2015 issue of Arthritis Care & Research.

“We set out to investigate the motives of patients who completed the BeSt trial [Dutch acronym for Treatment Strategies for Rheumatoid Arthritis], a 10-year, follow-up study evaluating four dynamic treatment strategies in patients with early rheumatoid arthritis (RA). In this study, visits every three months and a treat-to-target strategy based on a dynamic treatment protocol with established antirheumatic medication were continued during the total follow-up period. At every visit, a physical examination was performed by a study nurse, as were laboratory tests, and multiple questionnaires were completed,” wrote the authors in their introduction.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The BeSt study included a high frequency of visits, many questionnaires and additional examinations, such as dual-energy X-ray absorptiometry and radiographs of hands and feet. After 10 years, 60% of the 508 enrolled patients were still under follow-up. First, investigators sought to determine which patients were most likely to drop out of the study. They found that these patients tended to be older and had worse functional disability, drug-free remission, little joint damage and/or more adverse events. In particular, patients with worse functional ability were likely to leave the study regardless of age. Not surprisingly, the arm that the patient was randomized into also played a role in the decision to drop from the study.

On the final visit of the 10-year study, patients were given a questionnaire to determine their motives for continued participation. The questionnaire included 19 statements that described possible reasons a patient would continue to participate in a clinical study. Patients were asked to select one or more reasons they continued to participate. Patients who continued in the BeSt study were motivated to contribute to research and help future patients. They were also more likely to continue if they were frequently monitored and had good experiences with the study protocol. These good experiences were most often the result of the study’s nurses, who were attentive, communicative and acknowledged the patient’s time investment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients who believed they were gaining an understanding of their disease and learning new treatment strategies also tended to stay enrolled in the study. This finding suggested that the newsletters and meetings for BeSt patients were beneficial. Indeed, most patients found the newsletters informative and interesting. Moreover, most patients attended one or more meetings, and many found the meetings to be informative, well organized and/or interesting.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis Care & Researchclinical trialspatient careRheumatoid Arthritis (RA)

Related Articles

    Break Barriers: Engaging Diverse Participants in Clinical Trials for Patients with Lupus

    September 14, 2023

    Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.

    10 Tips for Productive Medical Practice Staff Meetings

    November 17, 2015

    As a physician, you need to focus on your patients’ needs. As someone who owns or manages a rheumatology practice, you need to focus on your business’s needs. “This can feel like you’re not only wearing two different hats, but that you also have to be two different people,” says Virginia Fraser, global content specialist,…

    Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

    December 19, 2017

    Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

    Mitigate Risk and Increase Success of Lupus Clinical Trials

    August 1, 2010

    Design strategies from a Lupus Research Institute conference

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences